why choose us

Clinical Trials Search

Showing 14,810 of 132,963 result(s)
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

Status: Completed

Condition: Major Depressive Disorder

Interventions: The full duration of therapy will be six-weeks.
The route of administration will be oral.
The starting dose of the medication will be 10mg d

Date: 2023-02-24

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Status: Completed

Condition: Hypertension

Interventions: Placebo once daily for 12 weeks

Date: 2023-02-24

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

Status: Completed

Condition: Hypoxia-Ischemia, Brain

Interventions: The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (>

Date: 2023-02-24

Awake Axillary Impella 5.5 Placement - A Feasibility Trial

Status: NOT_YET_RECRUITING

Condition: Cardiogenic Shock

Interventions: It is an ultrasound guided brachial plexus nerve block at roots;trunks used to anesthetize the shoulder and upper arm.
Goal is to spread loc

Date: 2023-02-24

Aesthetic Outcome of Tie-over Bolster Application in Surgical Wounds

Status: Completed

Condition: Scarring

Interventions: Bolster will be sutured into place using peripheral non-absorbable anchoring sutures.

Date: 2023-02-24

Ketone Pharmacokinetic Study in HFrEF

Status: Completed

Condition: Heart Failure With Reduced Ejection Fraction

Interventions: (R)-3-hydroxybutyl (R)-3-hydroxybutyrate

Date: 2023-02-24

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

Status: Completed

Condition: B-Cell Lymphoma

Interventions:

Participants will be treated with escalating doses of modified T cells.

Dose level -1: 3 x 10^6 Dose level 1: 10 x 10^6 Dose level 2: 30 x 10

Date: 2023-02-24

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Status: Completed

Condition: Diffuse Large B Cell Lymphoma

Interventions: Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take

Date: 2023-02-24

Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing

Status: Completed

Condition: Genetic Predisposition to Disease

Interventions: Patient- and clinician-facing portal via secure link

Date: 2023-02-24

Study of Effect of Azeliragon in Patients Refractory to First-Line Metastatic Pancreatic Cancer

Status: Completed

Condition: Metastatic Pancreatic Cancer

Interventions: Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule

Date: 2023-02-24